SEC Comment Letter 0000000000-23-008578 to Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc.
Date: Aug. 8, 2023 · CIK: 0001677077 · Accession: 0000000000-23-008578
AI Filing Summary & Sentiment
File numbers found in text: 333-273610
Letter
United States securities and exchange commission logo August 8, 2023 Stephan Jackman Chief Executive Officer Alzamend Neuro, Inc. 3480 Peachtree Road NE, Second Floor, Suite 103 Atlanta, GA 30326 Re:Alzamend Neuro, Inc. Registration Statement on Form S-3 Filed August 2, 2023 File No. 333-273610 Dear Stephan Jackman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kenneth Schlesinger, Esq.
Show Raw Text
United States securities and exchange commission logo
August 8, 2023
Stephan Jackman
Chief Executive Officer
Alzamend Neuro, Inc.
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, GA 30326
Re:Alzamend Neuro, Inc.
Registration Statement on Form S-3
Filed August 2, 2023
File No. 333-273610
Dear Stephan Jackman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Kenneth Schlesinger, Esq.